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Introduction 
Gait disorders are common among people with 
neuromuscular impairments –60% of the patients1–  
and generally have a high impact on their quality of 
life2. Lack of physical activity increases the risk of 
secondary health conditions such as respiratory and 
cardiovascular complications, bowel/bladder 
dysfunction, obesity, osteoporosis and ulcers3–7; which 
can further diminish life expectancy3,4. Therefore, 
walking recovery is one of the main rehabilitation 
priorities for patients with a neuromuscular 
impairment8,9. 
Wearable exoskeletons are emerging as a 
revolutionary device for gait rehabilitation, mainly due 
to both the active participation required from the user 
promoting physical activity10 and the possibility to work 
as an assistive device in the community. In fact, the 
number of research studies during the past 10 years 
has shown a large increase following the general 
tendency of rehabilitation robotics11. Although 
wearable exoskeletons are starting to be used in 
clinical practice, their efficacy is still not clear. 
This study provides a comprehensive overview on 
wearable powered exoskeletons for overground 
rehabilitation without body weight support in people 
with neuromuscular impairments.  
Methods 
We searched for scientific publications in four online 
databases from 2000 until 18th March 2019 using the 
following search terms: (exoskeleton OR orthos* OR 
exoskeletal) AND (robot* OR power*OR active) AND 
(walk* OR gait) AND ((leg OR lower) AND (limb OR 
extremity)) AND (rehabilitation* OR clinical* OR pilot) 
NOT (body weight support OR BWS OR treadmill OR 
upper OR hand OR arm). This literature search 
resulted in 855 publications, 57 of which were added in 
a second search for commercial exoskeletons: 175 in 
PubMed, 348 in Web of Science, 296 in Scopus and 
36 in IEEE Xplore. Additionally, 29 studies were 
identified from commercial exoskeleton websites. 
Finally, 89 studies were included in this review. 
Results 
In this review 26 exoskeletons have been identified, 
from which only five have FDA approval or/and CE 
mark and are commercially available (i.e., Ekso, HAL, 
Indego, REX and ReWalk). Regarding the type of 
neuromuscular disorder, SCI patients are the main 
target, with 60% of the total amount of patients from all 
the included studies, followed by stroke (29%) and 
other disorders (11%; Figure 1).  Table 1 shows that 
exoskeletons for pathologies with more severe gait 
impairments tend to use exoskeletons with more active 
joints.  We also found that the majority of devices are 
intended for adults and only one of the 26 
exoskeletons is intended for pediatric patients12. 
The number of degrees of freedom (DOF) in 
wearable exoskeletons ranges from 1 to 6, although 
the most frequent number is 4 DOF (2 per each leg). 
Joints can be passive, active or may be fixed (primarily 
in the ankle). From the 26 exoskeletons selected in 
this review, 22 present an active knee joint and only 
seven present passive joints (6: ankle, 1: hip). We also 
found that 16 out of the 26 exoskeletons actively assist 
two or more joints (12: hip-knee, 4: hip-knee-ankle), 
while the rest actively assist a single joint (1: hip, 6: 
knee, 3: ankle).   
 
Figure 1: Number of patients studied depending on the exoskeleton active joints number (left), mean and standard 
deviation (SD) of the device weight vs pathology (middle), and mean and SD of the device weight vs exoskeleton active 
joints number (right) 
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Table 1. Number of exoskeletons for pathology depending 
on the number of DOF 
Pathology 1 DOF 2 DOF 3 DOF 
SCI 2 9 3 
Stroke 4 2 2 
Other 6 4 1 
 
Exoskeletons with two active joints are the most 
representative and present the widest variability 
regarding the weight (22.98 ± 9.86 kg) (Figure 1). 
Surprisingly, the exoskeletons with two-active joints 
are heavier than those with three, although the 
heaviest exoskeleton is REX (38 kg) with three active 
joints. Interestingly, the majority of SCI patients have 
been studied with a two-active joint exoskeleton and 
all of them have an active knee joint. In addition, 
Exoskeletons for SCI patients have the highest weight 
(20.31 ± 9.38 kg), independently of the number of 
active joints (Figure 1).  
Outcome measures for evaluating ambulation are 
the most used in clinical studies (44%). This is 
followed by biomechanics measures (17%), which is 
ahead of energy expenditure (14%), balance and level 
of assistance (13%) and physiological improvements 
(8%). Finally, the assessment of usability and comfort 
(3%) is the least frequent (Figure 2). 
The most frequent outcome measures are gait 
speed, the 10 meter walk test (10MWT), the 6 minute 
walk test (6MWT) and the time up and go test (TUG), 
which  all of them belong to the ambulation 
assessments category. Regarding the biomechanics 
category, knee and hip joint angles are the most 
common outcome measures.  
Discussion 
SCI is the main target pathology for wearable 
exoskeletons, provably due to its high prevalence, high 
level of impairment and associated costs. 
Nevertheless, wearable exoskeletons are also starting 
to be used in other pathologies such as stroke, 
multiple sclerosis and cerebral palsy. 
Although there are exoskeletons with active hip, 
knee and ankle joints, users still require support 
devices such as crutches, walkers and canes to 
guarantee the users¶ balance during exoskeleton 
assisted walking. Therefore, current research is 
focusing on finding new control algorithms to improve 
balance. 
Clinical studies proving safety and efficacy of 
wearable exoskeletons for rehabilitation therapy are 
mainly focused on ambulation assessments instead of 
centered in physiological and psychological changes. 
Despite the great potential that wearable exoskeletons 
can offer, only a few studies assess the improvement 
related to the secondary health conditions. For 
example, Baunsgaard et al.13 and Juszczak et al.14 are 
the only studies that have measured bowel/bladder 
function. Moreover, they are, together with Jayaraman 
et al.15, the only studies looking into quality of life, 
being the latter the only one measuring the level of 
depression. 
The outcome measures varied across studies and 
made comparisons difficult. Clinical guidelines with 
standard sets of outcome measures would provide the 
possibility for benchmarking among devices. Solutions 
to unify technologies and provide comparable 
measures among exoskeletons are being proposed. 
For example the EUROBENCH 
(http://eurobench2020.eu/)16 project is working to 
establish standard benchmarking methods for 
exoskeletons to facilitate comparisons among the 
available solutions. 
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Figure 2. Analysis of the outcome measures used in clinical 
studies. Percentage is expressed over the total number of 
studies included in this review. 
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